Skip to main content
Harsh R. Shah
( out of 90 reviews )

Harsh R. Shah, DO

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
801-585-2626
  • Languages Spoken: English, Hindi, Gujarati

    Harsh Shah DO is an Assistant Professor of Medicine in the Division of Hematology at the Huntsman Cancer Center, University of Utah.

    Dr. Shah’s clinical expertise is in treatment of various lymphomas, such as Hodgkin’s Lymphoma, T-cell Lymphomas, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, CLL, etc. He has a research interest in immunotherapy resistance pathways in treatment of Hodgkin Lymphomas, particularly the role of Tumor Associated Macrophages. He is also interested in outcomes research and novel educational strategies for medical students, residents, and fellows.

    He completed his internal medicine training at Indiana University in Indianapolis and hematology and oncology fellowship at Karmanos Cancer Institute/Wayne State University in Detroit, Michigan. He is certified in both hematology and oncology.

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 90 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 19, 2023
    HUNTSMAN CANCER CENTER

    Dr Shah seems to be a very caring Doctor, and a great listener. I felt very comfortable with him and my husband thinks we have a good Doctor taking care of me.

    August 06, 2023
    HUNTSMAN CANCER CENTER

    Love and respect for Dr. Shah. He cares so much about patients needs.

    August 05, 2023
    HUNTSMAN CANCER CENTER

    He listens and helps me understand my disease.

    July 23, 2023
    HUNTSMAN CANCER CENTER

    He explained information well, never seemed rush, very thorough, hes caring and brings comfort to the patient and their family. Very positive throughout the entire course of treatment, which brings hope and comfort.

    July 22, 2023
    HUNTSMAN CANCER CENTER

    Dr. Shah is very knowledgeable and explained my treatment plan very well.

    May 27, 2023
    HUNTSMAN CANCER CENTER

    Like all Dr.s he is very busy.

    May 25, 2023
    HUNTSMAN CANCER CENTER

    Dr. Shah is fantastic.

    May 22, 2023
    HUNTSMAN CANCER CENTER

    I felt he was very concerned with my condition, answered all my questions, explained everything that I was going to be going through. Very helpful

    May 13, 2023
    HUNTSMAN CANCER CENTER

    Havent seen Dr Shah for a few months

  • Languages Spoken: English, Hindi, Gujarati

    Harsh Shah DO is an Assistant Professor of Medicine in the Division of Hematology at the Huntsman Cancer Center, University of Utah.

    Dr. Shah’s clinical expertise is in treatment of various lymphomas, such as Hodgkin’s Lymphoma, T-cell Lymphomas, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, CLL, etc. He has a research interest in immunotherapy resistance pathways in treatment of Hodgkin Lymphomas, particularly the role of Tumor Associated Macrophages. He is also interested in outcomes research and novel educational strategies for medical students, residents, and fellows.

    He completed his internal medicine training at Indiana University in Indianapolis and hematology and oncology fellowship at Karmanos Cancer Institute/Wayne State University in Detroit, Michigan. He is certified in both hematology and oncology.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology-Oncology - Karmanos Cancer Institute - Wayne State University Fellow
    Internal Medicine - Indiana University School of Medicine Resident
    Professional Medical Osteopathic Medicine - Kirksville College of Osteopathic Medicine - AT Still University of Health Sciences D.O.
    Biomedical Engineering - University of Michigan M.S.E.
    Undergraduate Biomedical Engineering - University of Michigan B.S.E.

    Selected Publications

    Journal Article

    1. Goyal G, Lau KW, Wang X, Davidoff AJ, Huntington SF, Jamy O, Calip G, Shah H, Stephens DM, Miksad R, Parikh RB, Takvorian S, Neparidze N, Seymour EK (2023). The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Netw Open, 6(6), e2316642. (Read full article)
    2. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes. Haematologica, 108(11), 3025-3032. (Read full article)
    3. Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Ramakrishnan Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL (2023). Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma. Clin Cancer Res. (Read full article)
    4. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (2022). Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. Cancer Med, 12(3), 2624-2636. (Read full article)
    5. Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Arai S, Chang C, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Murphy J, Ansell S, Jagadish D, Orellana-Noia V, Diefenbach C, Iyenger S, Rappazzo KC, Mishra R, Choi Y, Nowakowski GS, Advani RH, Micallef IN (2023). Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Am J Hematol. (Read full article)
    6. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao R (2022). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leuk Lymphoma, 64(2), 1-8. (Read full article)
    7. Shah H, Jang H, Kim S, Halwani AS (2022). A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race. Br J Haematol. (Read full article)
    8. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney DK (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Adv Radiat Oncol, 7(6), 101035. (Read full article)
    9. Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA (2022). Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study. Clin Cancer Res, 28(15), 3242-3247. (Read full article)
    10. Shah H, Jang H, Singh P, Kosti J, Kin A, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Ramchandren R, Kim S, Deol A (2021). Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents. Leuk Lymphoma, 63(4), 813-820. (Read full article)
    11. Shah HR, Stephens DM (2021). Is there a role for anti-CD20 antibodies in CLL? Hematology Am Soc Hematol Educ Program, 2021(1), 68-75. (Read full article)
    12. Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins MP, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers AA, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law JY, Karmali R, Shah HR, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko JM, Cohen JB, Portell CA (2021). Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood, 139, 413-423. (Read full article)
    13. Shah H, Stephens D, Seymour J, Maddocks K (2021). Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas. Am Soc Clin Oncol Educ Book, 41, 1-18. (Read full article)
    14. Vaishampayan U, Shah H, Asad MF, Shi D, Dickow B, Suisham S, Domina J, Cher ML, Samantray J, Aoun HD (2020). Adrenal Metastases as Sanctuary Sites in Advanced Renal Cancer. J Kidney Cancer VHL, 7(4), 1-7. (Read full article)
    15. Shah H, Kim S, Singh P, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Deol A (2019). Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts. Am J Hematol, 95(2), 198-204. (Read full article)
    16. Shah H, Vaishampayan U (2018). Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment. Target Oncol, 13(6), 679-689. (Read full article)
    17. Shah H, Bradford C, Sayar H (2015). Acute Promyelocytic Leukemia Presenting with Severe Marrow Fibrosis. Case Rep Hematol, 2015, 826894. (Read full article)

    Review

    1. Salem AE, Shah HR, Covington MF, Koppula BR, Fine GC, Wiggins RH, Hoffman JM, Morton KA (2022). PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies. [Review]. Cancers (Basel), 14(23). (Read full article)

    Case Report

    1. Shah H, McPherson K, Mansour A, Ramirez-Santrich C, Nassiri M, Shahda S (2016). Neuroendocrine Differentiation of a Primary BRAF Mutant Colon Cancer in a Patient With a History of Hairy Cell Leukemia. Clin Colorectal Cancer, 15(4), e235-e239. (Read full article)

    Letter

    1. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. [Letter to the editor]. Am J Hematol, 98(7), E172-E174. (Read full article)
    2. Shah H, Kim S, Klimecki S, Charlson K, Uberti J, Schiffer CA, Fiala MA, Seymour E (2022). Racial disparities in time to hematopoietic cell transplant among patients with hematologic malignancies at a large urban academic center. [Letter to the editor]. Bone Marrow Transplant, 57, 1213-1215. (Read full article)
  • News & Podcasts